Pueblo, CO - (NewMediaWire) - March 07, 2019 - CannaGrow Holdings, Inc. (OTC PINK: CGRW), A Liaison and Consultant providing turnkey solutions to licensed growers -- CannaGrow Holdings, Inc. announces the Huerfano County Building Department has issued a Temporary Certificate of Occupancy, as of March 6, 2019, based upon the completion of construction of the 1,600 sq. ft. steel building to be used exclusively for the Drying, Curing, and Packaging of the Cannabis being harvested at the Colorado Buffalo Ranch Facility. Delmar Janovec, CEO, stated, “Like everything else that has been built at the Colorado Buffalo Ranch Facility, the new building is State of the Art. The facility is 100% Climate Controlled, designed and built exclusively for Drying, Curing, and Packaging. The different computerized systems will work concurrently to eliminate humidity fluctuations caused by the extreme variance of temperature ranges within each 24-hour period in Southern Colorado. A special heavy-duty foam insulation was used throughout the entire building to stabilize indoor temperatures within a few degrees. Humidifier and Dehumidifier Systems were installed along with cutting edge Sensory Technology. Janovec went on to say, "Our objective was to create an ideal hermetic and sanitary environment to eliminate any potential mold, mildew, or fungus threats that can occur during the Drying, Curing, and Packaging Process, and that is exactly what has been accomplished. This 1600 sq. ft. facility will adequately handle the winter production cycles currently taking place in the six (6) 2,880 sq. ft. Climate Controlled IGC Ranger Series 2000 Greenhouses in addition to the Summer/Fall harvest that have already proven to be in excess of one thousand (1,000) pounds of product. With this building project checked off of the list we can start to look toward the future expansion into Phases III, IV, and V of our Master Plan."Rod Clawson, “Managing Director of Category One Botanicals, the Licensed Grower at the Colorado Buffalo Ranch Facility added, I am continually amazed at how far C1B has come since receiving the Colorado State Recreational Growers License back in April of 2016. With a committed developer like NuGro Industries and a Property Manager like CannaGrow Holdings, I can see Category One Botanicals taking a lead role in the Cannabis Industry in the State of Colorado.”CannaGrow Holdings, Inc., the Liaison and Representative for NuGro Industries, will continue in its capacity of providing oversight as the Property Manager, working with the State/County Agencies and Category One Botanicals, LLC, the Licensed Grower for the facilities. The completion of this project will now provide the company the basis to begin generating revenues from Licensed Growers subleasing the Turnkey facilities being built to the specifications of Consultants, Dr. John P. Janovec, and Jason Wells.About CannaGrow Holdings, Inc.:CannaGrow Holdings, Inc. has entered the Medical/Recreational Cannabis Industry as a Lessor, Liaison, and Consultant to licensed Growers providing them with turnkey Growing Facilities in the State of Colorado. The Company intends to expand this business model within this industry as business opportunities evolve whereby providing for the highest return to its shareholders.CannaGrow Holdings, Inc. does not and will not, until Federal law allows, grow, harvest, distribute, or sell marijuana or any substance that violates the laws of the United States of America.CannaGrow Holdings, Inc. encourages the public to read the above information in conjunction with its year-end statement for December 31, 2017, and the quarterly statements filed in calendar year 2018, at: www.otcmarkets.com. The information contained in this press release may include forward-looking statements. Forward-looking statements usually contain the words "may," "could," "possibly," "feel," "estimate," "anticipate," "believe," "expect," or similar expressions that involve risks and uncertainties. These risks and uncertainties include the Company's uncertain profitability, need for ...

Houston, TX, March 06, 2019 (NewMediaWire) -- AngioSoma, Inc. (OTC: SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief LLC, whose patented process and procedures treat the root cause of diabetes, instead of just the symptoms, resulting in patient improvement greater than with conventional treatment. Diabetes Relief Adds Key Milestones for 2019Diabetes Relief is meeting its goals for new licensed facilities by adding a third Houston captive facility and licensing new centers in Austin, California, and Florida. “Diabetes Relief is poised to improve the lives of millions of diabetics all over the world,” said Scott Hepford, Manager of Diabetes Relief LLC. Diabetes Relief’s Georgia Facility Exceeds ExpectationsDiabetes Relief reports that its licensee in Southeast Georgia has exceeded all hopes for profitability and patient improvements and is looking to expand to Atlanta. “This is what we have envisioned for the Company, and it is exciting to see it happen,” stated Brian Loveridge, MD, Regional Medical Director for Diabetes Relief LLC. “As Diabetes Relief continues to see improvement where conventional treatment has failed, the demand for its patented product are booming,” Dr. Loveridge added. Kerrie Dawson, CEO of DR’s first Georgia expansion, reported that “DR is worth the investment in so many ways for a practice, and we have saved one lady’s leg from amputation!” Diabetes Relief Licensed Facilities Grow to 11With the addition of licensed facilities in Jacksonville, Florida, and Thousand Oaks, California, Diabetes Relief’s patented treatment is now offered in 11 facilities and the company is working hard to keep up with the demand for licenses. “We are making plans for a comprehensive peer-reviewed, double-blind study of our amazing process that is changing so many lives once believed hopeless,” said Dr. Stanley Lewis, the Company’s Chief Medical Officer, “while handling the many requests for licenses.” ABOUT DIABETES RELIEF LLC Diabetes Relief LLC is a privately-held company that began in 2015 with one facility in Houston. Diabetes Relief’s patented process helps patients with all metabolic disorders, dominated by diabetes. Patients report improvements with Diabetes Relief's physiologic insulin administration that they have found nowhere else and with no other treatment or prescription drugs. Its rapidly growing licensees now provide services and products in 5 states and 3 other countries that promote healthier living and an improved quality of life for those living with diabetes and other metabolic dysfunction. Information and patient testimonials are available at www.diabetesrelief.com.ABOUT ANGIOSOMA, INC.AngioSoma, Inc. (https:// angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.NOTICE REGARDING FORWARD LOOKING STATEMENTSSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.CONTACT AngioSoma, Inc. Alex Blankenship investors@AngioSoma.com (832) 781-8521

Los Angeles, California, March 06, 2019 (NewMediaWire) -- EUREKA Vapor is pleased to announce that it has entered into a binding letter of intent (“LOI”) for the acquisition of all issued and outstanding shares of Eureka Vapor LLC and all of its subsidiaries (“Eureka”) by North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) ("NORTHBUD" or the "Company"). EUREKA Vapor is a U.S. multi-state cannabis operator.Eureka, through its wholly-owned subsidiaries holds Manufacturing and Distribution licenses in the states of California and Colorado. Eureka manufactures and sells a premium line of disposable vapor pens as well as multi-use cartridge-style vapor pens and hardware. Eureka has been operating in California and Colorado since 2011 and 2015, respectively, showing significant organic growth year over year. In 2018, Eureka recognized revenue of approximately CAD$11.5 million* with a net profit margin of 16%* from its California and Colorado operations. Eureka anticipates further growth in revenue due to anticipated changes to retail regulation of adult cannabis use in California. Eureka products are currently available in over 100 retail stores. (*all figures are unaudited). For more information about Eureka Vapor, visit: www.eurekavapor.com. “Aligning ourselves with NORTHBUD provides Eureka with both exposure to the Canadian public markets as well as the largest federally legal adult-use market in the world,” says Justin Braune, CEO of Eureka Vapor. “We will be working with the NORTHBUD team to introduce our product line into the Canadian market for the fourth quarter of 2019 when vape pens will be permitted.”“The opportunity to partner with a recognized brand in some of the most developed retail markets in North America is an exciting development for NORTHBUD,” says Ryan Brown, CEO of NORTHBUD. “We believe that vape cartridges represent a high margin and high-growth product segment of the market. The Eureka team are proven operators and possess an unmatched product knowledge which is evidenced by the strong brand loyalty that they have established.”About North Bud Farms Inc.North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. The Company is constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms Inc. will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.For more information visit: www.northbud.comAbout Eureka Vapor LLC.Headquartered in Los Angeles, California, EUREKA Vapor was founded in 2011 and holds licenses in both California and Colorado. EUREKA Vapor's multi state operation (MSO) manufactures and sells a premium line of vaporizer cartridges, disposable vapor pens and proprietary vaporizer batteries designed to work with their highly sought-after CO2 extracted oil. Using their refined extraction processes and techniques developed over almost a decade of extracting, EUREKA Vapor is committed to providing the cleanest and safest natural oil cartridges in the industry. Long referred to as one of the leaders in the industry, EUREKA has one of the most loyal customer bases in the category which reflects their commitment to honesty and transparency above all else. EUREKA continually looks for innovative ways to improve and refine their product offerings in order to deliver the best, most consistent vaping experience in the industry. For more information visit: www.eurekavapor.comFOR ADDITIONAL INFORMATION, PLEASE CONTACT: sales@eurekavapor.comJustin Braune justin@eurekavapor.com

SOUTH ORANGE, NJ, March 06, 2019 (NewMediaWire) -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will issue its fourth quarter and year-end 2018 financial results on Tuesday, March 12, 2019. The company will also host a conference call at 10:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.Participants may dial into the following number to access the call: 866-652-5200. International callers may use +1-412-317-6060. Please ask to be joined into the Nephros conference call. A replay of the call can be accessed until March 19, 2019 at 1-877-344-7529 or 1-412-317-0088 for international callers, and entering Replay Access Code: 10129217. An audio archive of the call will be available shortly after the call on the Nephros investor relations page at https://www.nephros.com/investor-relations/.About Nephros, Inc.Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, known as ultrafilters. Nephros ultrafilters are primarily used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas), viruses, and endotoxins from water. They provide barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients.For more information about Nephros, please visit the company’s website at www.nephros.com. Contact: Investor Relations Contact: Andy Astor CFO, Nephros andy@nephros.com (201) 345-0824